230 related articles for article (PubMed ID: 9252680)
21. The potential of farnesyltransferase inhibitors as cancer chemotherapeutics.
Gibbs JB; Oliff A
Annu Rev Pharmacol Toxicol; 1997; 37():143-66. PubMed ID: 9131250
[TBL] [Abstract][Full Text] [Related]
22. [Anti tumor activity of farnesyl transferase inhibitor].
Yoshimatsu K; Nagasu T
Gan To Kagaku Ryoho; 1997 Jan; 24(2):145-55. PubMed ID: 9030225
[TBL] [Abstract][Full Text] [Related]
23. Development of highly potent inhibitors of Ras farnesyltransferase possessing cellular and in vivo activity.
Leftheris K; Kline T; Vite GD; Cho YH; Bhide RS; Patel DV; Patel MM; Schmidt RJ; Weller HN; Andahazy ML; Carboni JM; Gullo-Brown JL; Lee FY; Ricca C; Rose WC; Yan N; Barbacid M; Hunt JT; Meyers CA; Seizinger BR; Zahler R; Manne V
J Med Chem; 1996 Jan; 39(1):224-36. PubMed ID: 8568812
[TBL] [Abstract][Full Text] [Related]
24. Design and synthesis of non-peptide Ras CAAX mimetics as potent farnesyltransferase inhibitors.
Qian Y; Vogt A; Sebti SM; Hamilton AD
J Med Chem; 1996 Jan; 39(1):217-23. PubMed ID: 8568811
[TBL] [Abstract][Full Text] [Related]
25. XR3054, structurally related to limonene, is a novel inhibitor of farnesyl protein transferase.
Donaldson MJ; Skoumas V; Watson M; Ashworth PA; Ryder H; Moore M; Coombes RC
Eur J Cancer; 1999 Jun; 35(6):1014-9. PubMed ID: 10533487
[TBL] [Abstract][Full Text] [Related]
26. NMR studies of novel inhibitors bound to farnesyl-protein transferase.
Koblan KS; Culberson JC; Desolms SJ; Giuliani EA; Mosser SD; Omer CA; Pitzenberger SM; Bogusky MJ
Protein Sci; 1995 Apr; 4(4):681-8. PubMed ID: 7613466
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956.
Nagasu T; Yoshimatsu K; Rowell C; Lewis MD; Garcia AM
Cancer Res; 1995 Nov; 55(22):5310-4. PubMed ID: 7585593
[TBL] [Abstract][Full Text] [Related]
28. Prevention of farnesylation of c-Ha-Ras protein enhances synergistically the cytotoxic action of doxorubicin in cycling but not in quiescent cells.
Wesierska-Gadek J; Kramer M; Schmid G
J Cell Biochem; 2006 Dec; 99(6):1664-76. PubMed ID: 16823773
[TBL] [Abstract][Full Text] [Related]
29. Geranylgeranyl diphosphate-based inhibitors of post-translational geranylgeranylation of cellular proteins.
Macchia M; Jannitti N; Gervasi G; Danesi R
J Med Chem; 1996 Mar; 39(7):1352-6. PubMed ID: 8691464
[TBL] [Abstract][Full Text] [Related]
30. Clavaric acid: a triterpenoid inhibitor of farnesyl-protein transferase from Clavariadelphus truncatus.
Jayasuriya H; Silverman KC; Zink DL; Jenkins RG; Sanchez M; Pelaez F; Vilella D; Lingham RB; Singh SB
J Nat Prod; 1998 Dec; 61(12):1568-70. PubMed ID: 9868169
[TBL] [Abstract][Full Text] [Related]
31. Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-ras in transgenic mice.
Mangues R; Corral T; Kohl NE; Symmans WF; Lu S; Malumbres M; Gibbs JB; Oliff A; Pellicer A
Cancer Res; 1998 Mar; 58(6):1253-9. PubMed ID: 9515813
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines.
Lerner EC; Zhang TT; Knowles DB; Qian Y; Hamilton AD; Sebti SM
Oncogene; 1997 Sep; 15(11):1283-8. PubMed ID: 9315095
[TBL] [Abstract][Full Text] [Related]
33. Lupane derivatives from Lophopetalum wallichii with farnesyl protein transferase inhibitory activity.
Sturm S; Gil RR; Chai HB; Ngassapa OD; Santisuk T; Reutrakul V; Howe A; Moss M; Besterman JM; Yang SL; Farthing JE; Tait RM; Lewis JA; O'Neill MJ; Farnsworth NR; Cordell GA; Pezzuto JM; Kinghorn AD
J Nat Prod; 1996 Jul; 59(7):658-63. PubMed ID: 8759161
[TBL] [Abstract][Full Text] [Related]
34. Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects.
Feldkamp MM; Lau N; Guha A
Oncogene; 1999 Dec; 18(52):7514-26. PubMed ID: 10602510
[TBL] [Abstract][Full Text] [Related]
35. Selective cytotoxicity of farnesylamine to pancreatic carcinoma cells and Ki-ras-transformed fibroblasts.
Ura H; Obara T; Shudo R; Itoh A; Tanno S; Fujii T; Nishino N; Kohgo Y
Mol Carcinog; 1998 Feb; 21(2):93-9. PubMed ID: 9496909
[TBL] [Abstract][Full Text] [Related]
36. A cell-based radioligand binding assay for farnesyl: protein transferase inhibitors.
Lobell RB; Davide JP; Kohl NE; Burns HD; Eng WS; Gibson RE
J Biomol Screen; 2003 Aug; 8(4):430-8. PubMed ID: 14567795
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of Ras prenylation: a signaling target for novel anti-cancer drug design.
Lerner EC; Hamilton AD; Sebti SM
Anticancer Drug Des; 1997 Jun; 12(4):229-38. PubMed ID: 9199657
[TBL] [Abstract][Full Text] [Related]
38. A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines.
Sepp-Lorenzino L; Ma Z; Rands E; Kohl NE; Gibbs JB; Oliff A; Rosen N
Cancer Res; 1995 Nov; 55(22):5302-9. PubMed ID: 7585592
[TBL] [Abstract][Full Text] [Related]
39. [Inhibitors of isoprenylation of ras p21].
Yoshimatsu K
Gan To Kagaku Ryoho; 1997 Sep; 24(11):1495-502. PubMed ID: 9309147
[TBL] [Abstract][Full Text] [Related]
40. [Effect of d-limonene, Salvia miltiorrhiza and turmeric derivatives on membrane association of Ras gene product and gap junction intercellular communication].
Chen X; Shuzo O; Li Y; Han R
Yao Xue Xue Bao; 1998 Nov; 33(11):821-7. PubMed ID: 12016941
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
